Dr. Joshua K. Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 2025 ASCO Annual Meeting, highlighting what patients should ...

In an interview with Pharmaceutical Executive, Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, discussed the company’s expanding efforts in solid tumors, a space where it is still ...

Inside ASCO 2025: Big data drops and a towering campaign By Ayla Ellison, Angus Liu, Gabrielle Masson, Zoey Becker Jun 6, 2025 10:39am The Top Line ASCO 2025 Enhertu Johnson & Johnson ...

Session ID: 2025-07-04:dfc7b8c17c83ea48a7aa25 Player Element ID: vjs_video_3 ...

ASCO 2025 may be over, but the insights are just beginning. This “Spotlight On” page is your hub for ongoing post-event coverage, including expert interviews, key takeaways, and video content ...

Updates in metastatic NSCLC from ASCO 2025 include data from TROPION-Lung02 on Dato-DXd, KRYSTAL-7 on first-line adagrasib, and zipalertinib from REZILIENT1, presented by Dr Jonathan Goldman.

BioLineRx Ltd. (NASDAQ:BLRX) is among the best growth stocks to invest in for the next 5 years. H.C. Wainwright reaffirmed its Buy rating on BioLineRx Ltd.

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Jazz Pharmaceuticals Gets UBS Buy Rating After Strong ASCO 2025 Trial Results Published on July 2, 2025 at 2:46 am by Sheryar Siddiq in News ...

Leaders in oncology share why the American Society of Clinical Oncology (ASCO) meeting remains a top global gathering for breakthroughs, networking, and lifelong learning.

AbbVie presented new data from its novel antibody-drug conjugates (ADCs) at ASCO 2025, including telisotuzumab adizutecan (Temab-A) in advanced non-small cell lung cancer, ABBV-706 in high-grade ...

The anonymous survey included 16 items on demographics, disease stage, trial participation status, outcomes, and perceptions; the majority of participants were white (82%). Over three-quarters (78 ...